Beta-Amyrin

Beta-Amyrin

SCHEMBL3119711

CC1(C)CC[C@]2(C)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O)C(C)(C)C5CC[C@]43C)[C@H]2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 2/20 1.00
▸ ALOX5 P09917 4/20 0.79
▸ CES1 P23141 3/20 0.77
▸ CES2 O00748 1/20 0.77
▸ PTPN1 P18031 9/20 0.77
▸ AKR1B10 O60218 3/20 0.77
▸ AKR1B1 P15121 1/20 0.77
▸ POLB P06746 3/20 0.76
▸ PTPN2 P17706 3/20 0.76
▸ PSMB11 A5LHX3 2/20 0.76
▸ PSMA7 O14818 2/20 0.76
▸ PLA2G1B P04054 2/20 0.76
▸ PTPRC P08575 2/20 0.76
▸ PTPRF P10586 2/20 0.76
▸ F3 P13726 2/20 0.76
▸ PSMB1 P20618 2/20 0.76
▸ ACP1 P24666 2/20 0.76
▸ PSMA1 P25786 2/20 0.76
▸ PSMA2 P25787 2/20 0.76
▸ PSMA3 P25788 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Beta-Amyrin SCHEMBL17124229 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL1696465 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL12313094 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL18687837 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL377754 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL14828378 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL1696463 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL18376076 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL14226156 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1
Beta-Amyrin SCHEMBL2025280 1.00 USP2 (1.00) USP2ALOX5CES1CES2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160375074-A1 Botanical Extracts and Compounds from Castanea Plants and Methods of Use UNIV EMORY (US) 2016-12-29 — — US claimed
US-10675321-B2 Botanical extracts and compounds from Castanea plants and methods of use EMORY UNIVERSITY (US) 2020-06-09 — — US disclosed
US-20190125818-A1 Botanical Extracts and Compounds from Castanea Plants and Methods of Use UNIV EMORY (US) 2019-05-02 — — US disclosed
US-10195241-B2 Botanical extracts and compounds from Castanea plants and methods of use EMORY UNIVERSITY (US) 2019-02-05 — — US disclosed
US-20160375074-A1 Botanical Extracts and Compounds from Castanea Plants and Methods of Use UNIV EMORY (US) 2016-12-29 — — US disclosed
WO-2010009091-A2 ANTI-INFLAMMATORY AND ANTI-ALLERGY EXTRACTS FROM NETTLE HERBALSCIENCE GROUP, LLC (US) 2010-01-21 — — WO disclosed
US-20100009927-A1 Anti-Inflammatory and Anti-Allergy Extracts from Nettle HERBALSCIENCE GROUP LLC (US) 2010-01-14 — — US disclosed
US-7618946-B2 Analgesic compounds, extracts containing same and methods of preparation GRIFFITH UNIVERSITY (AU) 2009-11-17 — — US disclosed
US-20070270375-A1 Novel Analgesic Compounds, Extracts Containing Same and Methods of Preparation JARLMADANGAH BURU ABORIGINAL CORPORATION (AU) 2007-11-22 — — US disclosed
EP-1687320-A1 NOVEL ANALGESIC COMPOUNDS, EXTRACTS CONTAINING SAME AND METHODS OF PREPARATION GRIFFITH UNIVERSITY (AU) 2006-08-09 — — EP disclosed
WO-2005051969-A1 NOVEL ANALGESIC COMPOUNDS, EXTRACTS CONTAINING SAME AND METHODS OF PREPARATION GRIFFITH UNIVERSITY (AU) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270375-A1 Novel Analgesic Compounds, Extracts Containing Same and Methods of Preparation DDOST, BBOX1, DAD1 USP2 1794/4885ALOX5 562/4885CES1 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback